Ind-Swift Laboratories Limited — Investor Meet, 20-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Ind-Swift Laboratories reported a strong Q1 FY27, with operating income up 21.16% YoY to ₹186.08 Cr. Operating EBITDA surged 2.85x to ₹33.32 Cr, with margins expanding to 17.91%. PAT jumped 2.04x to ₹24.68 Cr. The company is transitioning to a pure-play FDF manufacturer, with export own-brands contributing 57.20% of sales. New CDMO partnerships began contributing ₹5-6 Cr in Q1, with ₹100-130 Cr expected from two products this year. Management foresees sustainable 18%+ EBITDA margins and plans ₹250 Cr capex over 2.5 years, focusing on capacity and new products. The outlook reflects confidence in sustained growth.